Comparison of iodine-125 plaque brachytherapy and gamma knife stereotactic radiosurgery treatment outcomes for uveal melanoma patients

• Published in: Graefe's archive for clinical and experimental ophthalmology 2022-04, Vol.260 (4), p.1337-1343
• Main Authors: Guleser, Umit Yasar, Sarici, Ahmet Murat, Ucar, Didar, Gonen, Busenur, Sengul Samanci, Nilay, Özgüroğlu, Mustafa
• Format: Article
• Language: English
• Subjects: Acuity; Brachytherapy; Brachytherapy - adverse effects; Cataracts; Diagnosis; Glaucoma; Humans; Iodine; Iodine Radioisotopes; Medicine; Medicine & Public Health; Melanoma; Metastases; Metastasis; Oncology; Ophthalmology; Optic neuropathy; Patients; Radiation therapy; Radiosurgery; Retinopathy; Retrospective Studies; Survival; Treatment Outcome; Tumors; Uveal Neoplasms - diagnosis; Uveal Neoplasms - radiotherapy
• ISSN: 0721-832X; 1435-702X
• DOI: 10.1007/s00417-021-05472-x

Purpose To compare the efficacies of iodine-125 brachytherapy (IBT) and gamma knife stereotactic radiosurgery (GKRS) in the treatment of posterior uveal melanoma. Methods The demographic data and tumor characteristics at diagnosis of 201 patients treated with IBT and 52 patients treated with GKRS were recorded. The two treatments were then compared in terms of complications, local control, eye retention, metastasis, and overall survival rate. Results The median follow-up time was 56 months for the GKRS group and 45 months for the IBT group ( p  = 0.167). There were no significant differences in demographic data or tumor characteristics between the groups at diagnosis. Radiation retinopathy, radiation optic neuropathy, and neovascular glaucoma occurred at similar rates in both groups. However, radiation maculopathy and cataracts occurred more frequently in the GKRS group. The number of cases that have developed vision loss (worsening of best-corrected visual acuity on three or more lines on the Snellen chart) was significantly higher in the GKRS group (60%) compared to the IBT group (44%) ( p  = 0.048). Local control, metastasis, and 5-year overall survival rates were statistically similar in both groups. Conclusions GKRS can be preferred as an eye-sparing treatment option for posterior uveal melanoma in cases where brachytherapy cannot be used.